SCHEMBL29629210

SCHEMBL29629210

CNc1nccc(-c2sc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)nc2C)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 5/20 0.54
RAF1 P04049 4/20 0.54
MAPK14 Q16539 2/20 0.53
CDK8 P49336 4/20 0.51
CCNC P24863 3/20 0.51
KDR P35968 5/20 0.50
BLM P54132 1/20 0.50
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
DHODH Q02127 1/20 0.48
ARAF P10398 2/20 0.47
CCNA2 P20248 2/20 0.47
CDK2 P24941 2/20 0.47
CDK4 P11802 1/20 0.47
PLK1 P53350 1/20 0.47
RET P07949 2/20 0.47
MEN1 O00255 1/20 0.47
PLK4 O00444 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23068665 1.00 BRAF (0.54) BRAFRAF1MAPK14CDK8CCNC
SCHEMBL22684884 0.93 CDK2 (0.47) BRAFRAF1MAPK14CDK8CCNC
SCHEMBL22684877 0.92 CDK2 (0.49) BRAFRAF1MAPK14CDK8CCNC
SCHEMBL23068631 0.91 CDK2 (0.48) BRAFRAF1MAPK14CDK8KDR
SCHEMBL29629220 0.91 CDK2 (0.48) BRAFRAF1MAPK14CDK8KDR
SCHEMBL29629193 0.90 BLM (0.49) BRAFRAF1MAPK14KDRBLM
SCHEMBL23068623 0.90 BLM (0.49) BRAFRAF1MAPK14KDRBLM
SCHEMBL23068691 0.88 CDK2 (0.48) BRAFRAF1MAPK14KDRBLM
SCHEMBL22684844 0.88 CDK2 (0.51) KDRBLMCCNA2CDK2CDK4
SCHEMBL29629247 0.88 CDK2 (0.51) KDRBLMCCNA2CDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS AUCENTRA THERAPEUTICS PTY LTD (AU) 2023-03-23 US disclosed
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents AUCENTRA HOLDINGS PTY LTD (AU) 2022-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230092876-A1 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS CDK8, CDK18, CDK9 BRAF 556/4885RAF1 460/4885MAPK14 446/4885
US-11325900-B2 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents CDK8, CDK18, CDK9 BRAF 556/4885RAF1 460/4885MAPK14 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.